MONTGOMERY, Texas--(BUSINESS WIRE)--EVSC--
Endovasc Inc. (OTCBB:EVSC), a drug development company
that pioneers new cardiovascular and metabolic drug therapies,
announced positive results from the Company's Liprostin(TM) Phase II
Clinical Trial at the Georgian Angiology and Vascular Center. This
site, in addition to measuring the trials' primary end points of
maximum walking distance and pain free walking distance, monitored
transcutaneous oxygen pressure (TcPO2) in the extremities of patients
in the trial.
Endovasc is pleased to announce that at the conclusion of the
trial, patients at this site showed a significant improvement in 02
pressure. The TcPO2 test measures the level of oxygen flow to
extremities as associated in the skin tissue and is often used in
clinical trials as important endpoints to assess wound healing. This
arm of the trial provided data supporting the theory that Liprostin
holds promise for treatment of ischemic ulcers and wound healing.
"We thank Dr. Mamuka Bokuchava and his team at the Georgian
Angiology and Vascular Center for collecting this important data in
our Phase II Liprostin trial. According to Dr. Bokuchava, a majority
of the twenty-three patients showed a clinically significant increase
in their TcPO2 levels," said Dr. Diane Dottavio, CEO and President of
Endovasc Inc. "After the six treatments of Liprostin the patients
improved about 35% on average and sustained this improvement level one
month post treatment. These exciting results support Liprostin for the
treatment of vascular maladies such as ischemic and diabetic leg
ulcers."
The Georgian Angiology and Vascular Center was the first clinical
site to begin enrolling patients in Endovasc's open-label,
multi-center study of Liprostin for patients who suffer from critical
limb ischemia (CLI) and intermittent claudication (leg pain), but do
not require angioplasty. Critical Limb Ischemia (CLI) is a severe
blockage of the arteries that impairs blood flow to the hands, legs
and lower extremities, resulting in insufficient levels of oxygen in
the affected areas. While CLI is often caused by an acute condition,
such as a blood clot, more often it is the result of a chronic,
progressive condition, such as Peripheral Arterial Disease (PAD). An
estimated 10 million Americans have peripheral arterial disease, of
which 4.1 million have pain or intermittent claudication.
Endovasc's Liprostin is a liposome-encapsulated form of
prostaglandin E-1 (PGE-1). PGE-1 is known to be a potent vasodilator
and platelet inhibitor, as well as an anti-inflammatory and
anti-thrombotic agent. The encapsulated formulation (Liprostin) has
been shown to improve the therapeutic effectiveness of PGE-1,
positively impacting many areas of treatment, such as heart attacks,
occlusive disease, ischemic ulcers, critical limb salvage, and
arthritis.

About Endovasc

Endovasc, Inc., established in 1996, is an innovative drug
development company with two new cardiovascular and metabolic drug
therapies. Endovasc's mission is to design the delivery, and release
of drugs to their intended targets in an efficient and controlled
manner. For more information about Endovasc, please visit www.endovasc.com.

Safe Harbor

This news release includes statements that are not historical
facts and are considered "forward-looking" within the meaning of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements reflect Endovasc's current views about
future events. They are identified by their use of terms and phrases
such as "believe," "expect," "plan," "anticipate", "possibility" and
similar expressions identifying their forward-looking character.
Investors should not rely on these forward-looking statements as
assurances of future events, because such statements are inherently
subject to a variety of risks, uncertainties and other factors that
could cause actual results to differ materially from the Company's
expectations. The factors that may affect the outcome of such
expectations include, but are not limited to factors detailed from
time to time in the Company's filings with the Securities and Exchange
Commission.

KEYWORD: TEXAS
INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL MEDICAL PHARMACEUTICAL MEDICAL PHARMACEUTICAL
SOURCE: Endovasc Inc.

CONTACT INFORMATION:
FOCUS Partners LLC
Investor Relations:
David Zazoff, 212-752-9445

------------------
You Must Adapt To Your Opportunities And Weaknesses. You Can Use A Variety Of Approaches And Still Have A Consistant Result. - Sun Tzu, "The Art Of War"

Do Da Due.....But Be Damn Quick About It. - Dardadog, "Da Art Of Daytrading"

------------------
You Must Adapt To Your Opportunities And Weaknesses. You Can Use A Variety Of Approaches And Still Have A Consistant Result. - Sun Tzu, "The Art Of War"

Do Da Due.....But Be Damn Quick About It. - Dardadog, "Da Art Of Daytrading"

------------------
You Must Adapt To Your Opportunities And Weaknesses. You Can Use A Variety Of Approaches And Still Have A Consistant Result. - Sun Tzu, "The Art Of War"

Do Da Due.....But Be Damn Quick About It. - Dardadog, "Da Art Of Daytrading"